384 related articles for article (PubMed ID: 24175719)
1. Cariprazine, a new, orally active dopamine D2/3 receptor partial agonist for the treatment of schizophrenia, bipolar mania and depression.
Veselinović T; Paulzen M; Gründer G
Expert Rev Neurother; 2013 Nov; 13(11):1141-59. PubMed ID: 24175719
[TBL] [Abstract][Full Text] [Related]
2. Cariprazine for the Treatment of Schizophrenia: A Review of this Dopamine D3-Preferring D3/D2 Receptor Partial Agonist.
Citrome L
Clin Schizophr Relat Psychoses; 2016; 10(2):109-19. PubMed ID: 27440212
[TBL] [Abstract][Full Text] [Related]
3. Cariprazine, an orally active D2/D3 receptor antagonist, for the potential treatment of schizophrenia, bipolar mania and depression.
Gründer G
Curr Opin Investig Drugs; 2010 Jul; 11(7):823-32. PubMed ID: 20571978
[TBL] [Abstract][Full Text] [Related]
4. Cariprazine in bipolar disorder: clinical efficacy, tolerability, and place in therapy.
Citrome L
Adv Ther; 2013 Feb; 30(2):102-13. PubMed ID: 23361832
[TBL] [Abstract][Full Text] [Related]
5. Cariprazine in schizophrenia: clinical efficacy, tolerability, and place in therapy.
Citrome L
Adv Ther; 2013 Feb; 30(2):114-26. PubMed ID: 23361833
[TBL] [Abstract][Full Text] [Related]
6. Mechanism of action of cariprazine.
Stahl SM
CNS Spectr; 2016 Apr; 21(2):123-7. PubMed ID: 26956157
[TBL] [Abstract][Full Text] [Related]
7. The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial.
Durgam S; Starace A; Li D; Migliore R; Ruth A; Németh G; Laszlovszky I
Bipolar Disord; 2015 Feb; 17(1):63-75. PubMed ID: 25056368
[TBL] [Abstract][Full Text] [Related]
8. Clinical potential of cariprazine in the treatment of acute mania.
Altınbaş K; Guloksuz S; Oral ET
Psychiatr Danub; 2013 Sep; 25(3):207-13. PubMed ID: 24048386
[TBL] [Abstract][Full Text] [Related]
9. Cariprazine for the Treatment of Bipolar Disorder.
Findlay LJ; El-Mallakh PL; El-Mallakh RS
Perspect Psychiatr Care; 2017 Jul; 53(3):148-155. PubMed ID: 27059102
[TBL] [Abstract][Full Text] [Related]
10. Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability.
Citrome L
Expert Opin Drug Metab Toxicol; 2013 Feb; 9(2):193-206. PubMed ID: 23320989
[TBL] [Abstract][Full Text] [Related]
11. Cariprazine Treatment of Bipolar Depression: A Randomized Double-Blind Placebo-Controlled Phase 3 Study.
Earley W; Burgess MV; Rekeda L; Dickinson R; Szatmári B; Németh G; McIntyre RS; Sachs GS; Yatham LN
Am J Psychiatry; 2019 Jun; 176(6):439-448. PubMed ID: 30845817
[TBL] [Abstract][Full Text] [Related]
12. Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile.
Kiss B; Horváth A; Némethy Z; Schmidt E; Laszlovszky I; Bugovics G; Fazekas K; Hornok K; Orosz S; Gyertyán I; Agai-Csongor E; Domány G; Tihanyi K; Adham N; Szombathelyi Z
J Pharmacol Exp Ther; 2010 Apr; 333(1):328-40. PubMed ID: 20093397
[TBL] [Abstract][Full Text] [Related]
13. Comparative Tolerability of Dopamine D2/3 Receptor Partial Agonists for Schizophrenia.
Keks N; Hope J; Schwartz D; McLennan H; Copolov D; Meadows G
CNS Drugs; 2020 May; 34(5):473-507. PubMed ID: 32246399
[TBL] [Abstract][Full Text] [Related]
14. Cariprazine to Treat Schizophrenia and Bipolar Disorder in Adults.
Edinoff A; Ruoff MT; Ghaffar YT; Rezayev A; Jani D; Kaye AM; Cornett EM; Kaye AD; Viswanath O; Urits I
Psychopharmacol Bull; 2020 Sep; 50(4):83-117. PubMed ID: 33012874
[TBL] [Abstract][Full Text] [Related]
15. Safety and tolerability of cariprazine in patients with acute exacerbation of schizophrenia: a pooled analysis of four phase II/III randomized, double-blind, placebo-controlled studies.
Earley W; Durgam S; Lu K; Laszlovszky I; Debelle M; Kane JM
Int Clin Psychopharmacol; 2017 Nov; 32(6):319-328. PubMed ID: 28692485
[TBL] [Abstract][Full Text] [Related]
16. The Novel Antipsychotic Cariprazine (RGH-188): State-of-the-Art in the Treatment of Psychiatric Disorders.
De Berardis D; Orsolini L; Iasevoli F; Prinzivalli E; de Bartolomeis A; Serroni N; Mazza M; Valchera A; Fornaro M; Vecchiotti R; Carano A; Sepede G; Vellante F; Matarazzo I; Pompili M; Perna G; Conti C; Segura-García C; Martinotti G; Di Giannantonio M
Curr Pharm Des; 2016; 22(33):5144-5162. PubMed ID: 27396597
[TBL] [Abstract][Full Text] [Related]
17. Cariprazine:New dopamine biased agonist for neuropsychiatric disorders.
De Deurwaerdère P
Drugs Today (Barc); 2016 Feb; 52(2):97-110. PubMed ID: 27092339
[TBL] [Abstract][Full Text] [Related]
18. Effect of cariprazine across the symptoms of mania in bipolar I disorder: Analyses of pooled data from phase II/III trials.
Vieta E; Durgam S; Lu K; Ruth A; Debelle M; Zukin S
Eur Neuropsychopharmacol; 2015 Nov; 25(11):1882-91. PubMed ID: 26419293
[TBL] [Abstract][Full Text] [Related]
19. Brain uptake and distribution of the dopamine D3 /D2 receptor partial agonist [11 C]cariprazine: an in vivo positron emission tomography study in nonhuman primates.
Tóth M; Varrone A; Steiger C; Laszlovszky I; Horváth A; Kiss B; Gyertyán I; Adham N; Halldin C; Gulyás B
Synapse; 2013 May; 67(5):258-64. PubMed ID: 23238770
[TBL] [Abstract][Full Text] [Related]
20. An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial.
Durgam S; Starace A; Li D; Migliore R; Ruth A; Németh G; Laszlovszky I
Schizophr Res; 2014 Feb; 152(2-3):450-7. PubMed ID: 24412468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
